NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

Just starting to read the 85 page document and right at the start it struck me that the Magistrate is under the faulty notion that the entire trial all took place in 2022. He obviously does not know much about NWBO but a lot more about spoofing.

In 2022, DCVax®-L underwent a 331-patient Phase 3 clinical trial for the
treatment of GBM. (Id. ¶ 3). Plaintiffs allege that both the survival and safety data
from the trial were “excellent,” and that DCVax®-L is expected to have future value
beyond the treatment for which it was tested in 2022. (Id. ¶¶ 4, 45)